This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Dementias  • Neurogenetics  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Neurology, Other  • Review  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Introducing FTDP-17 (MAPT) and FTDP-17 (PGRN)

Bradley F. Boeve, MD; Mike Hutton, PhD

Arch Neurol. 2008;65(4):460-464.

Frontotemporal dementia with parkinsonism (FTDP) is a major neurodegenerative syndrome, particularly for those with symptoms beginning before age 65 years. A spectrum of degenerative disorders can present as sporadic or familial FTDP. Mutations in the gene encoding the microtubule-associated protein tau (MAPT; OMIM +157140) on chromosome 17 have been found in many kindreds with familial FTDP. Several other kindreds with FTDP had been linked to chromosome 17, but they had ubiquitin-positive inclusions rather than tauopathy pathology and no mutations in MAPT. This conundrum was solved in 2006 with the identification of mutations in the gene encoding progranulin (PGRN; OMIM *138945), which is only 1.7 Mb centromeric to MAPT on chromosome 17. In this review, we compare and contrast the demographic, clinical, radiologic, neuropathologic, genetic, and pathophysiologic features in patients with FTDP linked to mutations in MAPT and PGRN, highlighting the many similarities but also a few important differences. Our findings describe an intriguing oddity of nature in which 2 genes can cause a similar phenotype through apparently different mechanisms yet reside so near to each other on the same chromosome.

Author Affiliations: Divisions of Behavioral Neurology and Movement Disorders, Department of Neurology, Mayo Clinic, Rochester, Minnesota (Dr Boeve); Mayo Alzheimer's Disease Research Center, and Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program of the Mayo Foundation, Rochester, Minnesota, and Jacksonville, Florida (Drs Boeve and Hutton); and Neurogenetics Laboratory, Department of Neuroscience, Mayo Clinic, Jacksonville, Florida (Dr Hutton).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Progress on Progranulin
Boeve
Arch Neurol 2010;67:145-147.
FULL TEXT  

Anesthesia and the Old Brain
Tang et al.
Anesth. Analg. 2010;110:421-426.
ABSTRACT | FULL TEXT  

With or without FUS, it is the anatomy that dictates the dementia phenotype
Weintraub and Mesulam
Brain 2009;132:2906-2908.
FULL TEXT  

Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations
Whitwell et al.
Neurology 2009;73:1058-1065.
ABSTRACT | FULL TEXT